This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic
and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine,
Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma
This study will evaluate the safety, pharmacokinetics, and pharmacodynamic effects of a novel
anti-cancer drug, GZ17-6.02 administered to patients with advanced solid tumors or lymphoma,
which have progressed after receiving standard/approved therapy or where there is no approved
This study will determine the maximum tolerated dose (MTD) and the dose limiting toxicities
(DLT) of GZ17-6.02 monotherapy and in combination with standard-of-care oncology treatments
and to establish the dose of GZ17-6.02 recommended for future monotherapy and combination
therapies phase II oncology clinical studies.
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.